Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Despite some outstanding drug-development successes, the mouse version of multiple sclerosis has been worryingly unreliable at screening human treatments.
Most new treatments for multiple sclerosis are for patients with the relapsing–remitting form of the disease. Those with the more advanced, progressive type are being left behind.
More than 100 variations in the genome have been linked to multiple sclerosis. Researchers are now trying to find the overlap with other auto-immune conditions, and understand how environmental factors interact with genes to trigger disease.
Researchers are still a long way from using stem cells to halt the decline caused by multiple sclerosis and to restore patients' health. But they are following some promising trails.
For decades, drugs have barely managed to slow the progression of multiple sclerosis. Therapies are now emerging that may even help to reverse the disease — but are they worth the risk?